 |
|
Advent gives SEP acquisition boost
Speciality European Pharma (SEP) has secured €15 million (£10 million) from Advent Venture Partners. The investment is SPE’s first major financing round.
London-based SEP has used the financing to buy Swiss pharmaceutical company Proreo Pharma International. It also acquired the worldwide rights to Plenaxis - a treatment for prostate cancer - from US company Praecis Pharmaceuticals Plenaxis.
SEP’s chief executive Geoff McMillan says: 'The rationale for founding SEP was to acquire products with potential for a broader pan-European appeal and these two acquisitions very much fall into that sweet-spot.'
Launched by Advent in September 2006, SEP acquires pharmaceutical prescription products to develop and market in Europe. Rather than raising a war chest, the company will seek funding for specific acquisitions.
Advent has more than £500 million under management. General partner Patrick Lee is a non-executive director at SEP.
Related Articles |
Interesting links
Other Sector Watch
- Investment veteran airs fears over UK biotech Oct 21 2008
- Talking rubbish Jul 28 2008
- Crisis?– what crisis? Jul 01 2008
- Let the
drilling begin
May 13 2008 - Bargains on the high street
Mar 13 2008
M&A News
- Talbot Hughes McKillop’s Kroll MBO Nov 20 2008
- Cabinet member calls for more VC Nov 19 2008
- United Drug takes The Specials Lab medicine Nov 19 2008
- Public-to-private deals on the up Nov 18 2008
- RWE acquires Agrinergy stake Nov 18 2008
Special Offers
- 2008 AIM Guide: Jul 17 2007
- Growth Company Investor Magazine: Jul 17 2007
- Cash Shells 2007 - Research report Jul 17 2007
- Venture Capital Trusts Jul 04 2007
M&A Deals
- Amino Technologies to acquire Tilgin division Nov 20 2008
- Wincanton and Culina make chilled deal Nov 20 2008
- Devilfish makes Paramin Poker deal Nov 19 2008
- Arriva closes LNWR train maintenance deal Nov 19 2008
- UBM buys Xinhua PR Newswire Nov 18 2008
Business Diary
- M&A Expanding internationally 27th November
- Rosenblatt New Energy Awards 2009 25th February